Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968782 | 0.98 | KMT2A (0.43) | KMT2AMEN1ADORA2AADORA2BROCK2 | |
| SCHEMBL21217525 | 0.79 | ROCK2 (0.58) | KMT2AMEN1ROCK2ROCK1 | |
| SCHEMBL22967060 | 0.77 | ADORA2A (0.41) | KMT2AMEN1ADORA2AADORA2BLMNA | |
| SCHEMBL22966755 | 0.77 | ROCK2 (0.59) | KMT2AMEN1ROCK2ROCK1 | |
| SCHEMBL22967056 | 0.76 | ADORA2A (0.39) | KMT2AMEN1ADORA2AADORA2BROCK2 | |
| SCHEMBL21217523 | 0.75 | ROCK2 (0.58) | KMT2AMEN1ROCK2ROCK1HPGD | |
| SCHEMBL18792356 | 0.73 | ROCK2 (0.66) | ROCK2ROCK1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18792298 | 0.71 | ROCK2 (0.68) | KMT2AMEN1ROCK2ROCK1SMN1; SMN2 | |
| SCHEMBL22966757 | 0.71 | ROCK2 (0.54) | KMT2AMEN1ROCK2ROCK1LMNA | |
| SCHEMBL22966753 | 0.70 | ROCK2 (0.50) | KMT2AMEN1ROCK2ROCK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | KMT2A 2289/4885MEN1 2942/4885ADORA2A 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.